NEW YORK, Jan. 13, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies
investors of class action against Esperion Therapeutics, Inc.
(Esperion or "the Company") (Nasdaq: ESPR) and certain of its
officers. The class action was filed in the United
States District Court for the Eastern District of Michigan on behalf of a class consisting of
all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the
"Class Period"). Such investors are advised to contact Peretz Bronstein or his investor relations
analyst, Yael Hurwitz at
info@bgandg.com or 212-697-6484.
This lawsuit alleges that throughout the Class Period,
Defendants released materially false and misleading statements
regarding Esperion's business and prospects to shareholders,
including that there was no clear path to approval for ETC-1002,
and that the FDA had encouraged Esperion to initiate a
cardiovascular outcomes trial ("CVOT") and the completion of a CVOT
could be necessary prior to approval of ETC-1002. Following
this news, Esperion stock traded at artificially inflated prices
reaching as high as $82 per share in
intra-day trading, causing investors to suffer losses.
No Class has yet been certified in the above action. If you wish
to join this litigation you can visit the firm's website at:
http://www.bgandg.com/#!espr/jfi4h. You may also contact
Peretz Bronstein, Esq. or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email info@bgandg.com. Those who inquire by
e-mail are encouraged to include their mailing address and
telephone number. If you suffered a loss in Natural Health
Trends you have until March 14, 2016
to request that the Court appoint you as lead plaintiff. Your
ability to share in any recovery doesn't require that you serve as
a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-esperion-therapeutics-inc-espr-and-lead-plaintiff-deadline-march-14-2016-300203815.html
SOURCE Bronstein, Gewirtz & Grossman, LLC